retatrutide clinical trials saudi arabia Incretin-based therapies for the treatment of obesity-related diseases SFDA Approves Clinical Trial for
Description
Retatrutide (LY-3437943) is an investigational triple receptor agonist peptide that simultaneously activates three metabolic receptors: GLP-1, GIP, and glucagon
It handles the formula application so you can focus on protocol decisions rather than arithmetic
[DOI] [PubMed] [Google Scholar] 129.Karagiannis, T
It turns a broad class effect into a personalized decision
GLP-1 can also support microvascular health by inhibiting angiotensin II-NADPH oxidase, which reduces the production of reactive oxygen species in endothelial cells
Image courtesy of Svetlana Mojsov, taken from her personal lab notebooks
